Cat.No：GM-0220PV197
Product：Influenza A (H7N9) Luciferase Pseudotyped Virus
Cat.No：GM-0220PV197
Product：Influenza A (H7N9) Luciferase Pseudotyped Virus
| Cat. No. | Product | Store | Cat. No / Size | |
| GM-100399PLV-100 | Influenza A (H7N9) Luciferase Pseudotyped Virus | -80℃ | GM-0220PV197-96T | GM-0220PV197-960T |
| 100 μL/管*1管 | 100 μL/管*10管 | |||
H7N9 was expressed as a structural protein (gag-pol) of human immunodeficiency virus type I (HIV-1) and the coat proteins of influenza virus, hemagglutinin HA (GenBank ID: AGI60292.1) and neuraminidase NA (GenBank ID: AGI60295.1) ( Strain: A/Shanghai/4664T/2013) co-expressed in HEK-293T cells after self-assembling and wrapping nucleic acids expressing a luciferase reporter gene (Luciferase). The pseudovirus is a replication-defective virus that cannot produce new viral particles after infection, is safe, and has a structure highly similar to that of the true virus, and thus can be used for neutralizing antibody titer assays, inhibitor screening, viral invasion studies, and H7N9 vaccine development.
H7N9 pseudoviruses contain viral neutralizing antigens and have the ability to infect cells. When a sample has neutralizing activity, its ability to infect cells is diminished by interaction with the pseudovirus. By measuring the luciferase expression of each well with a multifunctional enzyme marker and comparing the values of the sample wells to be tested with the pseudovirus control, it is possible to determine whether the sample has neutralizing activity and to calculate the effective concentration of the sample in action. The neutralizing antibody titer is the reciprocal of the antibody dilution at 50% pseudovirus inhibition.
Cat.No：GM-0220PV197
Product：Influenza A (H7N9) Luciferase Pseudotyped Virus
| Cat. No. | Product | Store | Cat. No / Size | |
| GM-100399PLV-100 | Influenza A (H7N9) Luciferase Pseudotyped Virus | -80℃ | GM-0220PV197-96T | GM-0220PV197-960T |
| 100 μL/管*1管 | 100 μL/管*10管 | |||
H7N9 was expressed as a structural protein (gag-pol) of human immunodeficiency virus type I (HIV-1) and the coat proteins of influenza virus, hemagglutinin HA (GenBank ID: AGI60292.1) and neuraminidase NA (GenBank ID: AGI60295.1) ( Strain: A/Shanghai/4664T/2013) co-expressed in HEK-293T cells after self-assembling and wrapping nucleic acids expressing a luciferase reporter gene (Luciferase). The pseudovirus is a replication-defective virus that cannot produce new viral particles after infection, is safe, and has a structure highly similar to that of the true virus, and thus can be used for neutralizing antibody titer assays, inhibitor screening, viral invasion studies, and H7N9 vaccine development.
H7N9 pseudoviruses contain viral neutralizing antigens and have the ability to infect cells. When a sample has neutralizing activity, its ability to infect cells is diminished by interaction with the pseudovirus. By measuring the luciferase expression of each well with a multifunctional enzyme marker and comparing the values of the sample wells to be tested with the pseudovirus control, it is possible to determine whether the sample has neutralizing activity and to calculate the effective concentration of the sample in action. The neutralizing antibody titer is the reciprocal of the antibody dilution at 50% pseudovirus inhibition.
